+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Fetal Bovine Serum Market by Application and End User: Global Opportunity Analysis and Industry Forecast, 2018-2025

  • ID: 4828600
  • Report
  • Region: Global
  • 219 pages
  • Allied Analytics LLP
1 of 4
The global fetal bovine serum market was valued at $695 million in 2017 and is estimated to reach at $1,037 million by 2025, registering a CAGR of 5.1 % from 2018 to 2025.

Fetal bovine serum (FBS) is an ideal growth medium containing several nutrients and optimal combination of growth factors, which make it the most effective growth promoter for almost any cell culture system. In addition, the significantly lower content of antibodies compared to adult and newborn sera minimizes the risk of antibody cross-reaction with cells in culture. FBS finds its application in animal tissue culture and plant tissue culture, while reagents are used in various biotechnology applications such as diagnosis, laboratory research, drug development, and others.

Significant rise in biotechnological R&D pertaining to the introduction of novel biopharmaceuticals has led to an increase in demand for FBS. Moreover, increase in investments and funding for research interventions in both developed and developing countries boost the market growth. However, ethical & scientific concerns associated with the potential misuse of biotechnology research practices and dearth of skilled personnel hamper the market growth. Few fraud cases associated with the production of fetal bovine sera have been reported, which further restrains the growth of the market. Conversely, untapped potential of the emerging economies such as India, China, and others is anticipated to provide lucrative opportunities to the key players involved in the fetal bovine serum market.

The fetal bovine serum media market is segmented based on application, end user, and region. The applications covered in the study include biopharmaceuticals, cell culture, human and animal vaccine production, and others. Depending on end user, the market is classified into biotechnology & pharmaceutical industry, academic institute, and research laboratory. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS

The study provides an in-depth analysis of the global fetal bovine serum market along with the current trends and future estimations to elucidate the imminent investment pockets.
A comprehensive analysis of the factors that drive and restrict the market growth is provided.
A comprehensive quantitative analysis of the industry is provided from 2018 to 2025 to assist stakeholders to capitalize on the prevailing market opportunities.
An extensive analysis of the key segments of the industry helps to understand the global trends in the fetal bovine serum market.

KEY players and their strategies are provided to understand the competitive outlook of the industry.

KEY MARKET SEGMENTS
  • By Application
o Biopharmaceuticals
o Cell Culture
o Human & Animal Vaccine Production
o Others
  • By End User
o Biotechnology & Pharmaceutical Companies
o Academic Institute
o Research Laboratory
  • By Region
o North America
  • U.S.
  • Canada
  • Mexico
o Europe
  • UK
  • France
  • Germany
  • Italy
  • France
  • Rest of Europe
o Asia-Pacific
  • Japan
  • China
  • India
  • South Korea
  • Australia
  • Rest of Asia-Pacific
o LAMEA
  • Saudi Arabia
  • South Africa
  • Brazil
  • Rest of LAMEA
KEY MARKET PLAYERS
  • GE Healthcare
  • Merck KGaA (Sigma Aldrich)
  • HiMedia Laboratories Pvt., Ltd.
  • Bio-Techne
  • Biowest
  • Biological Industries
  • Atlas Biologicals
  • Rocky Mountain Biologicals
  • PAN-Biotech.
  • Thermo Fisher Scientific Inc.
The other players in the value chain include (profiles not included in the report)
  • Takara Bio, Inc.
  • Cyagen Biosciences
  • Tissue Culture Biologicals
  • Bovogen Biologicals Pty Ltd.
  • TCS Biosciences Ltd.
  • Corning Incorporated
  • Access Biologicals
  • Caisson Laboratories, Inc.
Note: Product cover images may vary from those shown
2 of 4
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.4. Research methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY
2.1. KEY FINDINGS OF THE STUDY
2.2. Key findings
2.2.1. Top impacting factors
2.2.2. Top investment pockets
2.3. CXO perspective

CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Parent/Peer Market Overview
3.3. Key Forces Shaping Fetal Bovine Serum Industry/Market
3.3.1. Low bargaining power of suppliers
3.3.2. Moderate bargaining power of buyers
3.3.3. Low threat of substitutes
3.3.4. Low intensity of rivalry
3.3.5. Moderate Threat of Substitution
3.4. Pricing Analysis
3.4.1. Pricing Analysis of Fetal Bovine Serum, By Region, 2018 & 2025
3.5. Market evolution/ Industry roadmap
3.6. Value Chain Analysis
3.7. Impact of government regulations on global fetal bovine serum market
3.8. Industry Pain point analysis
3.9. Case Studies
3.9.1. Case Study 01
3.10. Market dynamics
3.10.1. Drivers
3.10.1.1. Rise in R&D Investment
3.10.1.2. High demand of fetal bovine sera
3.10.1.3. Surge in biopharmaceutical production
3.10.2. Restraints
3.10.2.1. High price
3.10.2.2. Increased use of alternatives
3.10.3. Opportunities
3.10.3.1. Untapped potential of the emerging economies

CHAPTER 4: FETAL BOVINE SERUM MARKET, BY APPLICATION
4.1. Overview
4.2. Biopharmaceuticals
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis by country
4.3. Cell Culture
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis by country
4.4. Human and Animal Vaccine Production
4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market analysis by country
4.5. Others
4.5.1. Key market trends, growth factors, and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market analysis by country

CHAPTER 5: FETAL BOVINE SERUM MARKET, BY END USER
5.1. Overview
5.2. Biotechnology & Pharmaceutical Company
5.2.1. Market size and forecast, by region
5.2.2. Market analysis by country
5.3. Academic Institute
5.3.1. Market size and forecast, by region
5.3.2. Market analysis by country
5.4. Research Laboratory
5.4.1. Market size and forecast, by region
5.4.2. Market analysis by country

CHAPTER 6: FETAL BOVINE SERUM MARKET, BY REGION
6.1. Overview
6.2. North America
6.2.1. Key market trends and opportunities
6.2.2. Market size and forecast, by application
6.2.3. Market size and forecast, by end user
6.2.4. Market analysis by country
6.2.4.1. U.S. Market size and forecast, by application
6.2.4.2. Market size and forecast, by end user
6.2.4.3. Canada
6.2.4.4. Canada Market size and forecast, by application
6.2.4.5. Canada Market size and forecast, by end user
6.2.4.6. Mexico Market size and forecast, by application
6.2.4.7. Mexico Market size and forecast, by end user
6.3. Europe
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by application
6.3.3. Europe Market size and forecast, by end user
6.3.4. Europe Market size and forecast, by country
6.3.4.1. UK Market size and forecast, by application
6.3.4.2. UK Market size and forecast, by end user
6.3.4.3. Germany Market size and forecast, by application
6.3.4.4. Germany Market size and forecast, by end user
6.3.4.5. France Market size and forecast, by application
6.3.4.6. France Market size and forecast, by end user
6.3.4.7. Italy Market size and forecast, by application
6.3.4.8. Market size and forecast, by end user
6.3.4.9. Spain Market size and forecast, by application
6.3.4.10. Spain Market size and forecast, by end user
6.3.4.11. Rest of Europe Market size and forecast, by application
6.3.4.12. Rest of Europe Market size and forecast, by end user
6.4. Asia-Pacific
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by application
6.4.3. Market size and forecast, by end user
6.4.4. Market size and forecast, by country
6.4.4.1. China Market size and forecast, by application
6.4.4.2. China Market size and forecast, by end user
6.4.4.3. India Market size and forecast, by application
6.4.4.4. India Market size and forecast, by end user
6.4.4.5. Japan Market size and forecast, by application
6.4.4.6. Japan Market size and forecast, by end user
6.4.4.7. South Korea Market size and forecast, by application
6.4.4.8. South Korea Market size and forecast, by end user
6.4.4.9. Australia Market size and forecast, by application
6.4.4.10. Australia Market size and forecast, by end user
6.4.4.11. Rest of Asia-Pacific Market size and forecast, by application
6.4.4.12. Rest of Asia-Pacific Market size and forecast, by end user
6.5. LAMEA
6.5.1. Key market trends, growth factors and opportunities
6.5.2. Market size and forecast, by application
6.5.3. Market size and forecast, by end user
6.5.4. Market size and forecast, by country
6.5.4.1. Brazil Market size and forecast, by application
6.5.4.2. Brazil Market size and forecast, by end user
6.5.4.3. Saudi Arabia Market size and forecast, by application
6.5.4.4. Saudi Arabia Market size and forecast, by end user
6.5.4.5. Saudi Arabia Market size and forecast, by application
6.5.4.6. Saudi Arabia Market size and forecast, by end user
6.5.4.7. Rest of LAMEA Market size and forecast, by application
6.5.4.8. Rest of LAMEA Market size and forecast, by end user

CHAPTER 7: COMPETITIVE LANDSCAPE
7.1. INTRODUCTION
7.1.1. MARKET PLAYER POSITIONING, 2018
7.2. MARKET SHARE ANALYSIS OF TOP PLAYERS, 2018 (%)
7.3. TOP WINNING STRATEGIES
7.4. COMPETITIVE DASHBOARD
7.5. COMPETITIVE HEATMAP

CHAPTER 8: COMPANY PROFILES: FETAL BOVINE SERUM MARKET
8.1. BIO-TECHNE (ATLANTA BIOLOGICS)
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.1.5. Business performance
8.1.6. Key strategic moves and developments
8.2. SERA SCANDIA A/S (BIOWEST
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio
8.3. PAN-BIOTECH
8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Product portfolio
8.4. GE HEALTHCARE (A HEALTHCARE DIVISION OF GE COMPANY)
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Product portfolio
8.4.5. Business performance
8.5. HIMEDIA LABORATORIES PVT., LTD
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Product portfolio
8.6. BIOLOGICAL INDUSTRIES
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Product portfolio
8.7. ATLAS BIOLOGICALS
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product portfolio
8.8. Merck KGAA (SIGMA ALDRICH)
8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product portfolio
8.8.5. Business performance
8.8.6. Key strategic moves and developments
8.9. ROCKY MOUNTAIN BIOLOGICALS (RMBIO)
8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Product portfolio
8.10. THERMO FISHER SCIENTIFIC INC.
8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Product Portfolio
8.10.5. Business performance
8.11. Other Key Player Profile
8.11.1. Key player snapshot

CHAPTER 9: APPENDIX

*Full List of Tables and Figures Available on Enquiry.

Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
According to this report titled,'Fetal bovine serum Market by Application, and End User: Global Opportunity Analysis and Industry Forecast, 2018 - 2025,'The global fetal bovine serum market was valued at $695 million in 2017, and is projected to reach $ 1,037 million by 2025, growing at a CAGR of 5.1 % from 2018 to 2025. North America was the highest revenue contributor in 2017 and is anticipated to maintain the same trend throughout the forecast period.

Fetal bovine serum (FBS) is a nutrient growth supplement provided in laboratory and research settings for growth, proliferation, maintenance, and storage of microorganisms and other cell types such as stem cells, mammalian, and other cell lines. FBS is considered more appropriate as compared to the other animal sera available in the market, owing to the presence of additional hormones necessary for cell growth, proliferation, and differentiation of cells. Moreover, the quality of FBS is determined primarily at the blood collection site and the raw serum processing center. Appropriate collection is fundamental in maintaining the natural growth-promoting properties of fetal blood, thus achieving consistent and superior performance of the final FBS products. The growth of fetal bovine serum market size is primarily driven by the growing demand for biopharmaceuticals, rising biotech R&D activities in developing economies and increase in the support from government for research activities across the globe. However, significant increase in its price within recent years is anticipated to hamper the fetal bovine serum market growth. Conversely, untapped potential of emerging markets are anticipated to provide lucrative opportunities in the near future to the key players operating in the fetal bovine serum market.

Based on fetal bovine serum market trends by application, the cell culture segment accounted for the majority share of the global market in 2017. This is attributed to the fact that fetal bovine serum finds its application in performing various animal cell cultures. It is most widely used supplement for cell cultures.

Depending on end user, the biotechnology & pharmaceutical company segment generated the maximum revenue of in 2017, and is anticipated to exhibit prominent growth, due to significant rise in R&D for the development of drugs, human & animal vaccines and others.

Key Findings of the Fetal bovine serum Market:

Based on end user, research laboratories accounted for nearly one-fifth share of the fetal bovine serum industry in 2017.
The biopharmaceuticals application segment is anticipated to grow with the highest CAGR throughout the forecast period.
Region wise, North America accounted for nearly two-fifths of the global fetal bovine serum market share in 2017.
Asia-Pacific is anticipated to grow at the highest rate during the analysis period, followed by LAMEA.

North America was the leading revenue contributor to the global market in 2018, owing to increase in healthcare investments by manufacturers and surge in R&D expenditure for various biotechnology research purposes. In addition, U.S. is the largest exporter of fetal bovine serum across the globe. Asia-Pacific is expected to witness the highest growth rate throughout the forecast period, due to increase in biotechnology R&D regarding development of biopharmaceuticals & vaccines and increase in the penetration of key market players in this region. Moreover, rise in government initiatives towards improving biotechnology research sector further boosts the market growth in this region.

The report provides an extensive competitive analysis and profiles of the key market players, such as GE Healthcare, Merck KGaA (Sigma Aldrich), HiMedia Laboratories Pvt., Ltd, Bio-Techne, Biowest, Biological Industries, Atlas Biologicals, Rocky Mountain Biologicals, PAN-Biotech, and Thermo Fisher Scientific Inc. The other players in the value chain (not included in the report) include Takara Bio, Inc., Cyagen Biosciences, PeproTech, Inc., Avantor Performance Materials, Caisson Laboratories, Inc., Cell Culture Technologies LLC, and Biomol GmbH.
Note: Product cover images may vary from those shown
5 of 4

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...

Adroll
adroll